These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [The effect of neuroleptics on the social behavior disorders of schizophrenic patients]. Mahé V Encephale; 2003 Sep; 29(Pt 2):S28-30. PubMed ID: 14710533 [No Abstract] [Full Text] [Related]
25. Important issues in the drug treatment of schizophrenia. Davis JM; Schaffer CB; Killian GA; Kinard C; Chan C Schizophr Bull; 1980; 6(1):70-87. PubMed ID: 6102795 [TBL] [Abstract][Full Text] [Related]
26. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics. Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799 [No Abstract] [Full Text] [Related]
27. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. Meltzer HY; Sommers AA; Luchins DJ J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856 [TBL] [Abstract][Full Text] [Related]
28. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients]. Briken P; Nika E; Krausz M; Naber D Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946 [TBL] [Abstract][Full Text] [Related]
29. Risperidone: how good is the evidence for efficacy? Mattes JA Schizophr Bull; 1997; 23(1):155-61. PubMed ID: 9050121 [TBL] [Abstract][Full Text] [Related]
30. Novel neuroleptics in schizophrenia: theory and clinical relevance. Remington GJ Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S43-5. PubMed ID: 7533050 [No Abstract] [Full Text] [Related]
31. Should the CATIE study be a wake-up call? Ragins M Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608 [No Abstract] [Full Text] [Related]
32. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
33. [From neuroleptics toward antipsychotics: quality of life and schizophrenia]. Lançon C Encephale; 2003 Sep; 29(Pt 2):S43-6. PubMed ID: 14710537 [No Abstract] [Full Text] [Related]
34. Quality of life of schizophrenic patients on medications and implications for new drug trials. Awad AG Hosp Community Psychiatry; 1992 Mar; 43(3):262-5. PubMed ID: 1348238 [TBL] [Abstract][Full Text] [Related]
35. Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." Psychopharmacology (1980) 72:17-19. Angrist B; Rotrosen J; Gershon S Psychopharmacology (Berl); 2001 Nov; 158(3):219-21. PubMed ID: 11713609 [No Abstract] [Full Text] [Related]
36. [Clozapine and treatment of negative symptoms]. Lançon C; Farisse J; Llorca PM Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403 [TBL] [Abstract][Full Text] [Related]
38. Schizophrenia: recent advances in psychopharmacology. Sharma T Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500 [No Abstract] [Full Text] [Related]
39. Combined alprazolam and neuroleptic drug in treating schizophrenia. Bacher NM; Lewis HA; Field PB Am J Psychiatry; 1986 Oct; 143(10):1311-3. PubMed ID: 2876649 [No Abstract] [Full Text] [Related]